Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7477.074 | 1.0829 | 1.2684 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7477.074 | 1.2840 | 1.9697 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7477.074 | 1.2840 | 1.9697 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7477.074 | 1.4311 | 2.5253 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7477.074 | 1.4311 | 2.5253 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7477.074 | 0.9749 | 0.9211 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7477.074 | 0.9749 | 0.9211 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7477.074 | 1.2027 | 1.6779 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7477.074 | 1.2027 | 1.6779 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7477.074 | 0.8385 | 0.5137 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7477.074 | 0.8385 | 0.5137 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7477.074 | 0.4469 | -0.4403 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7477.074 | 0.4469 | -0.4403 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7477.074 | 0.3030 | -0.6972 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7477.074 | 0.3030 | -0.6972 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7477.074 | 0.1661 | -0.8830 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7477.074 | 0.1661 | -0.8830 | 0.6324 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14791.203 | 0.9983 | 0.9979 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14791.203 | 0.9983 | 0.9979 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14791.203 | 0.9796 | 0.9743 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14791.203 | 0.9796 | 0.9743 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14791.203 | 0.8694 | 0.8316 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14791.203 | 0.8694 | 0.8316 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14791.203 | 0.6216 | 0.4834 | 1.5910 | |
| LY2 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14791.203 | 0.6216 | 0.4834 | 1.5910 |